Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer's and Parkinson's disease

被引:58
|
作者
Sjodin, Simon [1 ,2 ]
Brinkmalm, Gunnar [1 ,2 ]
Ohrfelt, Annika [1 ,2 ]
Parnetti, Lucilla [3 ]
Paciotti, Silvia [4 ,5 ]
Hansson, Oskar [6 ,7 ]
Hardy, John [8 ,9 ]
Blennow, Kaj [1 ,2 ]
Zetterberg, Henrik [1 ,2 ,8 ,9 ]
Brinkmalm, Ann [1 ,2 ]
机构
[1] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Psychiat & Neurochem, House V3, SE-43180 Molndal, Sweden
[2] Sahlgrens Univ Hosp, Clin Neurochem Lab, Molndal, Sweden
[3] Univ Perugia, Lab Clin Neurochem, Neurol Clin, Perugia, Italy
[4] Univ Perugia, Dept Expt Med, Perugia, Italy
[5] Univ Perugia, Dept Med, Lab Clin Neurochem, Perugia, Italy
[6] Lund Univ, Dept Clin Sci Malmo, Clin Memory Res Unit, Lund, Sweden
[7] Skane Univ Hosp, Memory Clin, Malmo, Sweden
[8] UCL, Dept Mol Neurosci, Inst Neurol, Queen Sq, London, England
[9] UCL, UK Dementia Res Inst, London, England
基金
欧洲研究理事会; 瑞典研究理事会;
关键词
Alzheimer's disease; Biomarker; CSF; Mass spectrometry; Parkinson's disease; CEREBROSPINAL-FLUID BIOMARKERS; CHAPERONE-MEDIATED AUTOPHAGY; MILD COGNITIVE IMPAIRMENT; BETA-GLUCOCEREBROSIDASE ACTIVITY; PAIRED HELICAL FILAMENTS; ALPHA-SYNUCLEIN; APOLIPOPROTEIN-E; NEUROFIBRILLARY TANGLES; ASSOCIATION WORKGROUPS; DIAGNOSTIC GUIDELINES;
D O I
10.1186/s13195-019-0533-9
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background Increasing evidence implicates dysfunctional proteostasis and the involvement of the autophagic and endo-lysosomal system and the ubiquitin-proteasome system in neurodegenerative diseases. In Alzheimer's disease (AD), there is an accumulation of autophagic vacuoles within the neurons. In Parkinson's disease (PD), susceptibility has been linked to genes encoding proteins involved in autophagy and lysosomal function, as well as mutations causing lysosomal disorders. Furthermore, both diseases are characterized by the accumulation of protein aggregates. Methods Proteins associated with endocytosis, lysosomal function, and the ubiquitin-proteasome system were identified in the cerebrospinal fluid (CSF) and targeted by combining solid-phase extraction and parallel reaction monitoring mass spectrometry. In total, 50 peptides from 18 proteins were quantified in three cross-sectional cohorts including AD (N = 61), PD (N = 21), prodromal AD (N = 10), stable mild cognitive impairment (N = 15), and controls (N = 68). Results A pilot study, including subjects selected based on their AD CSF core biomarker concentrations, showed increased concentrations of several targeted proteins in subjects with core biomarker levels indicating AD pathology compared to controls. Next, in a clinically characterized cohort, lower concentrations in CSF of proteins in PD were found compared to subjects with prodromal AD. Further investigation in an additional clinical study again revealed lower concentrations in CSF of proteins in PD compared to controls and AD. Conclusion In summary, significantly different peptide CSF concentrations were identified from proteins AP2B1, C9, CTSB, CTSF, GM2A, LAMP1, LAMP2, TCN2, and ubiquitin. Proteins found to have altered concentrations in more than one study were AP2B1, CTSB, CTSF, GM2A, LAMP2, and ubiquitin. Interestingly, given the genetic implication of lysosomal function in PD, we did identify the CSF concentrations of CTSB, CTSF, GM2A, and LAMP2 to be altered. However, we also found differences in proteins associated with endocytosis (AP2B1) and the ubiquitin-proteasome system (ubiquitin). No difference in any peptide CSF concentration was found in clinically characterized subjects with AD compared to controls. In conclusion, CSF analyses of subjects with PD suggest a general lysosomal dysfunction, which resonates well with recent genetic findings, while such changes are minor or absent in AD.
引用
收藏
页数:16
相关论文
共 50 条
  • [31] Multicenter Alzheimer's and Parkinson's disease immune biomarker verification study
    Brosseron, Frederic
    Kolbe, Carl-Christian
    Santarelli, Francesco
    Carvalho, Stephanie
    Antonell, Anna
    Castro-Gomez, Sergio
    Tacik, Pawel
    Namasivayam, Aishwarya Alex
    Mangone, Graziella
    Schneider, Reinhard
    Latz, Eicke
    Wuellner, Ullrich
    Svenningsson, Per
    Sanchez-Valle, Raquel
    Luis Molinuevo, Jose
    Corvol, Jean-Christophe
    Heneka, Michael T.
    ALZHEIMERS & DEMENTIA, 2020, 16 (02) : 292 - 304
  • [32] Parkinson's disease and Alzheimer's disease: a Mendelian randomization study
    Han, Zhifa
    Tian, Rui
    Ren, Peng
    Zhou, Wenyang
    Wang, Pingping
    Luo, Meng
    Jin, Shuilin
    Jiang, Qinghua
    BMC MEDICAL GENETICS, 2018, 19
  • [33] Biomarker A plus T-: is this Alzheimer's disease or not? A combined CSF and pathology study
    Vromen, Eleonora M.
    de Boer, Sterre C. M.
    Teunissen, Charlotte E.
    Rozemuller, Annemieke
    Sieben, Anne
    Bjerke, Maria
    Visser, Pieter Jelle
    Bouwman, Femke H.
    Engelborghs, Sebastiaan
    Tijms, Betty M.
    BRAIN, 2023, 146 (03) : 1166 - 1174
  • [34] CSF and blood Kallikrein-8: a promising early biomarker for Alzheimer's disease
    Teuber-Hanselmann, Sarah
    Rekowski, Jan
    Vogelgsang, Jonathan
    von Arnim, Christine
    Reetz, Kathrin
    Stang, Andreas
    Joeckel, Karl-Heinz
    Wiltfang, Jens
    Esselmann, Herrmann
    Otto, Markus
    Tumani, Hayrettin
    Herring, Arne
    Keyvani, Kathy
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2020, 91 (01) : 40 - 48
  • [35] PET Radiopharmaceuticals for Alzheimer's Disease and Parkinson's Disease Diagnosis, the Current and Future Landscape
    Uzuegbunam, Bright Chukwunwike
    Librizzi, Damiano
    Yousefi, Behrooz Hooshyar
    MOLECULES, 2020, 25 (04):
  • [36] Autophagic and endo-lysosomal dysfunction in neurodegenerative disease
    Malik, Bilal R.
    Maddison, Daniel C.
    Smith, Gaynor A.
    Peters, Owen M.
    MOLECULAR BRAIN, 2019, 12 (01)
  • [37] CSF proteomic signature predicts progression to Alzheimer's disease dementia
    Vromen, Eleonora M.
    del Campo Milan, Marta
    Scheltens, Philip
    Teunissen, Charlotte E.
    Visser, Pieter Jelle
    Tijms, Betty M.
    ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS, 2022, 8 (01)
  • [38] Association between Sleep, Alzheimer's, and Parkinson's Disease
    Matsumoto, Sumire
    Tsunematsu, Tomomi
    BIOLOGY-BASEL, 2021, 10 (11):
  • [39] Alzheimer's disease CSF biomarkers: clinical indications and rational use
    Niemantsverdriet, Ellis
    Valckx, Sara
    Bjerke, Maria
    Engelborghs, Sebastiaan
    ACTA NEUROLOGICA BELGICA, 2017, 117 (03) : 591 - 602
  • [40] Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update
    del Campo, Marta
    Mollenhauer, Brit
    Bertolotto, Antonio
    Engelborghs, Sebastiaan
    Hampel, Harald
    Simonsen, Anja Hviid
    Kapaki, Elisabeth
    Kruse, Niels
    Le Bastard, Nathalie
    Lehmann, Sylvain
    Molinuevo, Jose L.
    Parnetti, Lucilla
    Perret-Liaudet, Armand
    Saez-Valero, Javier
    Saka, Esen
    Urbani, Andrea
    Vanmechelen, Eugeen
    Verbeek, Marcel
    Visser, Pieter Jelle
    Teunissen, Charlotte
    BIOMARKERS IN MEDICINE, 2012, 6 (04) : 419 - 430